MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145765 | Name: CGS-24592

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CGS-24592 is a selective and potent agonist of the adenosine A2A receptor, which is a subtype of the adenosine receptor found in the brain. The A2A receptor is involved in various neurological processes, including modulation of dopamine transmission and regulation of motor control. CGS-24592 has been studied primarily for its potential therapeutic effects in treating conditions like Parkinson's disease, where the adenosine A2A receptor plays a role in motor symptoms. By selectively activating this receptor, CGS-24592 may help improve motor function and reduce symptoms associated with Parkinson's disease.

Chemical Structure

CGS-24592
CGS-24592
CAS#147923-04-4

Theoretical Analysis

MedKoo Cat#: 145765

Name: CGS-24592

CAS#: 147923-04-4

Chemical Formula: C19H23N2O6P

Exact Mass: 406.1300

Molecular Weight: 406.37

Elemental Analysis: C, 56.16; H, 5.71; N, 6.89; O, 23.62; P, 7.62

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CGS-24592; CGS24592; CGS 24592;
IUPAC/Chemical Name
(S)-3-(3-([1,1'-biphenyl]-4-yl)-2-((phosphonomethyl)amino)propanamido)propanoic acid
InChi Key
MVRLTBIHUWUGAR-KRWDZBQOSA-N
InChi Code
1S/C19H23N2O6P/c22-18(23)10-11-20-19(24)17(21-13-28(25,26)27)12-14-6-8-16(9-7-14)15-4-2-1-3-5-15/h1-9,17,21H,10-13H2,(H,20,24)(H,22,23)(H2,25,26,27)/t17-/m0/s1
SMILES Code
OC(=O)CCNC(=O)[C@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NCP(O)(O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 406.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Maniara WM, Cipriano A, Powell ML. Quantitative analytical methods for the determination of a new hypertension drug, CGS 25462, and its metabolites (CGS 25659 and CGS 24592) in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998 Mar 20;706(2):287-94. doi: 10.1016/s0378-4347(97)00566-5. PMID: 9551815. 2: Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension. 2005 Jun;45(6):1145-52. doi: 10.1161/01.HYP.0000168944.29525.da. Epub 2005 May 16. PMID: 15897363. 3: Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S, Thuillez C. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol. 2004 Apr;43(4):489-94. doi: 10.1097/00005344-200404000-00003. PMID: 15085059. 4: Wright JL, Jeng AY, Battistini B. Effect of ECE and NEP inhibition on cigarette smoke-induced cell proliferation in the rat lung. Inhal Toxicol. 2001 Jun;13(6):497-511. doi: 10.1080/08958370117619. PMID: 11445889. 5: Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, Jeng AY, Battistini B. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens. 2005 Dec;18(12 Pt 1):1606-13. doi: 10.1016/j.amjhyper.2005.06.022. PMID: 16364833. 6: Iyer SN, Yamada K, Diz DI, Ferrario CM, Chappell MC. Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. J Cardiovasc Pharmacol. 2000 Jul;36(1):109-17. doi: 10.1097/00005344-200007000-00015. PMID: 10892668. 7: Pelletier S, Battistini B, Jeng AY, Sirois P. Effects of dual endothelin- converting enzyme/neutral endopeptidase inhibitors, CGS 26303 and CGS 26393, on lipopolysaccharide or interleukin-1 beta-stimulated release of endothelin from guinea pig tracheal epithelial cells. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S10-2. doi: 10.1097/00005344-199800001-00005. PMID: 9595386. 8: Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1998 Jan;31(1 Pt 2):356-61. doi: 10.1161/01.hyp.31.1.356. PMID: 9453328. 9: Pham D, Jeng AY, Escher E, Sirois P, Battistini B. Effects of a selective neutral endopeptidase and a nonselective neutral endopeptidase/endothelin- converting enzyme inhibitor on lipopolysaccharide-induced endotoxaemia in anaesthetized Sprague-Dawley rats. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S362-6. doi: 10.1097/00005344-200036051-00105. PMID: 11078421. 10: De Lombaert S, Ghai RD, Jeng AY, Trapani AJ, Webb RL. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem Biophys Res Commun. 1994 Oct 14;204(1):407-12. doi: 10.1006/bbrc.1994.2473. PMID: 7945387. 11: Jacob S, Deyo DJ, Cox RA, Traber DL, Herndon DN, Hawkins HK. Mechanisms of toxic smoke inhalation and burn injury: role of neutral endopeptidase and vascular leakage in mice. Toxicol Mech Methods. 2009 Mar;19(3):191-6. doi: 10.1080/15376510902725649. PMID: 19727335; PMCID: PMC2736052. 12: Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology. 2000 May;141(5):1699-704. doi: 10.1210/endo.141.5.7463. PMID: 10803579. 13: De Lombaert S, Erion MD, Tan J, Blanchard L, el-Chehabi L, Ghai RD, Sakane Y, Berry C, Trapani AJ. N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. J Med Chem. 1994 Feb 18;37(4):498-511. doi: 10.1021/jm00030a009. PMID: 8120868. 14: Caner HH, Kwan AL, Arthur A, Jeng AY, Lappe RW, Kassell NF, Lee KS. Systemic administration of an inhibitor of endothelin-converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage. J Neurosurg. 1996 Nov;85(5):917-22. doi: 10.3171/jns.1996.85.5.0917. PMID: 8893732. 15: Porter KE, Dickinson T, London NJ. Inhibition of neointima formation in an organ culture of human saphenous vein: a comparison of dual endothelin- converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition. J Vasc Surg. 2001 Sep;34(3):548-54. doi: 10.1067/mva.2001.115960. PMID: 11533610. 16: Pham D, Jeng AY, Plante S, Escher E, Battistini B. Inhibition of endothelin- converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery. Can J Physiol Pharmacol. 2002 May;80(5):450-7. doi: 10.1139/y02-059. PMID: 12056552. 17: Daull P, Blouin A, Sirois P, Nantel F, Jeng AY, Battistini B. Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S398-401. doi: 10.1097/01.fjc.0000166293.79948.09. PMID: 15838331. 18: Emoto N. [Physiological and pathophysiological roles of the endothelin converting enzymes]. Nihon Rinsho. 2004 Sep;62 Suppl 9:636-9. Japanese. PMID: 15506464. 19: Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest. 2000 Dec;106(11):1399-407. doi: 10.1172/JCI10536. PMID: 11104793; PMCID: PMC381465. 20: Sumitomo M, Asano T, Asakuma J, Asano T, Nanus DM, Hayakawa M. Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):260-6. doi: 10.1158/1078-0432.ccr-0798-3. PMID: 14734478.